2nd-line Treatment of Metastatic Colorectal Cancer

Phase 2 Terminated 83 enrolled Institut du Cancer de Montpellier - Val d'Aurelle

RandomizedParallel-groupOpen-labelTreatment

Summary

This phase 2 trial aims to evaluate the continued use of bevacizumab with raltitrexed and oxaliplatin combination versus FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer whose disease has progressed after irinotecan-based chemotherapy.

Timeline

Start: 2011-07-28
Primary completion: 2016-05-12
Completion: 2019-01

Publications

Samalin E, Senellart H, Thezenas S, Jacquot S, Ellis S, Akouz FK, Fiess C, Ramdani M, Portales F, Assenat E, Ychou M, Mineur L, Mazard T. The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. Oncologist. 2026 Feb 5;31(3):oyag006. doi: 10.1093/oncolo/oyag006.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Bevacizumab	Monoclonal antibody	7.5 mg/kg	Intravenous
Subject	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Raltitrexed	Small molecule	3 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	2400 mg/m2	Intravenous

2nd-line Treatment of Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications